BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 16, 2020
View Archived Issues
Macrolide resistance mechanism rescues mRNA from ribosome
Read More
Results from the NCI-MATCH subprotocol using T-DM1 in HER2-amplified histologies
Read More
European Commission grants marketing authorization for Isturisa
Read More
Lung cancer treatment options much improved, but resistance remains
Read More
New PCSK9 inhibitors discovered at Ra Pharmaceuticals
Read More
Jiangsu Vcare Pharmatech patents EGFR inhibitors
Read More
miR-107 as a new target for overcoming chemoresistance in CRC
Read More
Medshine Discovery identifies new IRAK-4 inhibitors
Read More
Novel TMEM16A potentiator shows promise in models of CF
Read More
Janssen R&D Ireland and Johnson & Johnson disclose anti-HBV compounds
Read More
Henan Tiansheng Taifeng Pharmaceutical Technology discovers compounds for HBV treatment
Read More
HDAC blockade seen to restore cardiopulmonary function in felines
Read More
New nonviral nanoparticles are safe and effective for gene therapy in pediatric brain cancer models
Read More
Phase IIb study of nebulized ensifentrine meets primary endpoints
Read More
Vertex's VX-814 enters phase II development for alpha1-antitrypsin deficiency
Read More
Sintilimab regimen meets primary endpoint in phase III non-small cell lung cancer trial
Read More
Preliminary findings from phase I study of Spero's SPR-206 support advancement of program
Read More
Neurodegeneration treatment candidate IW-6463 well tolerated in phase I study
Read More
GeneTx Biotherapeutics cleared to begin phase I/II study of GTX-102 in Angelman syndrome
Read More
Tmunity Therapeutics initiates phase I study of CART-TnMUC1
Read More
ART1, a novel therapeutic target in EGFR-mutated lung cancer
Read More
